Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.34 |
| ▸ | HTR3A | P46098 | 3/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5366414 | 0.79 | CHRM4 (0.35) | KDM4EALDH1A1NPC1RAB9AMAPT | |
| SCHEMBL5347636 | 0.78 | FYN (0.38) | ALDH1A1MAPTCHRNA7HTR3ACHRNB4 | |
| SCHEMBL5346288 | 0.76 | PDE10A (0.38) | KDM4EALDH1A1HSD17B10NPC1RAB9A | |
| SCHEMBL5358073 | 0.75 | CHRNA7 (0.36) | KDM4EALDH1A1HSD17B10RAB9ASMN1; SMN2 | |
| SCHEMBL2900828 | 0.74 | CHRNA7 (0.37) | ALDH1A1HSD17B10CHRNA7HTR3ACHRM4 | |
| SCHEMBL5358060 | 0.73 | CHRNA7 (0.39) | CHRNA7HTR3ACHRM4CHRM5CHRM1 | |
| Hydrochloric Acid SCHEMBL2900298 | 0.73 | CHRNA7 (0.39) | ALDH1A1HSD17B10CHRNA7HTR3ACHRNB4 | |
| SCHEMBL5350554 | 0.72 | CHRNA7 (0.38) | GAACHRNA7HTR3A | |
| SCHEMBL5355916 | 0.72 | CHRNA7 (0.38) | KDM4EALDH1A1GAAMAPTCHRNA7 | |
| SCHEMBL5353379 | 0.72 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | claimed |
| US-7223753-B2 | Diazabicyclic biaryl derivatives | NEUROSEARCH A/S (DK) | 2007-05-29 | — | — | US | disclosed |
| EP-1562945-B1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | disclosed |
| EP-1562945-A1 | 1,4-DIAZABICYCLO(3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2005-08-17 | — | — | EP | disclosed |
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | ANIONA APS (DK) | 2004-07-01 | — | — | US | disclosed |
| WO-2004043960-A1 | 1,4-DIAZABICYCLO (3,2,2)NONANE DERIVATIVES, PREPARATION AND THERAPEUTICAL USE THEREOF | NEUROSEARCH A/S (DK) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127491-A1 | Novel diazabicyclic biaryl derivatives | CHRNA6, CHRNA3, CHRNA2 | KDM4E 2840/4885ALDH1A1 1023/4885POLB 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.